Publication: Enhancement of sialylation in rIgG in glyco-engineered Chinese hamster ovary cells
Issued Date
2020-01-01
Resource Type
ISSN
15730778
09209069
09209069
Other identifier(s)
2-s2.0-85080972492
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Cytotechnology. (2020)
Suggested Citation
Thi Sam Nguyen, Ryo Misaki, Takao Ohashi, Kazuhito Fujiyama Enhancement of sialylation in rIgG in glyco-engineered Chinese hamster ovary cells. Cytotechnology. (2020). doi:10.1007/s10616-020-00381-z Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/53600
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Enhancement of sialylation in rIgG in glyco-engineered Chinese hamster ovary cells
Other Contributor(s)
Abstract
© 2020, Springer Nature B.V. Since about 70% of commercial biopharmaceutical products have been produced in Chinese hamster ovary (CHO) cells, this cell line is undeniably a workhorse for biopharmaceuticals production. Meanwhile, sialic acid terminals were reported to affect anti-inflammatory activity, antibody-dependent cellular cytotoxicity efficacy of IgG antibodies. Taking these findings together, we aimed to establish CHO cell lines that highly produce sialic acid terminals by overexpressing two N-acetylneuraminic acid-based key enzymes, α(2,6)-sialyltransferase and UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase using dihydrofolate reductase/methotrexate gene amplification method. Indeed, the number of total sialic acid terminal glycan structures increased tremendously, by 12-fold compared to the wild type in total protein extracts. With the methotrexate supplementation, a targeted cell line, CHOmt17-100, showed up to 1.4 times more sialylated structures of glycoforms in total proteins. Interestingly, immunoglobulin G, used as the model protein in CHOmt17-100, showed about 53% sialylated structures in its glycoforms. These resultant sialylated glycans exhibited more than approximately 14.5 times increase as compared to that of the wild type. Moreover, the resultant glycan structures mostly had N-acetylneuraminic acid terminals, while N-glycolylneuraminic acid terminal composition remained less than 5% as compared to the wild type. Engineered antibodies derived from CHO cell lines that produce high levels of sialic acid will contribute to the examination of glycoforms’ efficacy and usefulness toward bio-better products.